ORTHOCELL LIMITED — Director's Dealing 2019

May 23, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Introduced 30/09/2001
Name of entity:	Orthocell Limited
ABN:	57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes	of section 205G of the Corporations Act.
Name of Director:	Stewart Washer
Date of last notice:	11/05/2018

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)
Date of change	21/05/2019
No. of securities held prior to change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)	314,417 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 235,994 Ordinary Shares 95,842 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020

• See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Class changed	Ordinary Shares
Number acquired	366,742
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of fees based on formula set out in Notice of General Meeting lodged on ASX 18/04/2019 as follows: 85,851 - $0.1456 86,266 - $0.1449 94,625 - $0.1321 100,000 - $0.125
No. of securities held after change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)	314,417 Ordinary Shares 366,742 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 235,994 Ordinary Shares 95,842 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued in lieu of fees for the period Jan 2019-April 2019 as approved by shareholders at a general meeting on 20 May 2019

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Value/Consideration Note: if consideration is non-cash, provide details and an estimated valuation	N/A
Interest after changes	N/A

Part 3 – Closed Period

Part 3 – Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Name of entity:	Orthocell Limited
ABN:	57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes	of section 205G of the Corporations Act.
Name of Director:	Matthew Callahan
Date of last notice:	17/05/2019

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Callahan is a founder and director of Stone Ridge Ventures Pty Ltd which is the manager of the SRV Tech Trust, a venture capital fund. Mr Callahan is considered to have a relevant interest in these shares due to his position as a director or shareholder of the respective trustee companies and holds a beneficial interest in the SRV Trust. The SRV Trust is the carry trust for the SRV Tech Trust Mr Callahan is a director of the Trustee and a beneficiary of the Shenasaby trust Mr Callahan is a director of the Trustee and a beneficiary of the Shenasaby trust
Date of change	21 May 2019
No. of securities held prior to change
SRV Custodians Pty Ltd SRV Nominees Pty Ltd Shenasaby Investments Pty Ltd	7,570,000 Ordinary Shares 649,177 Ordinary Shares 12,500 Ordinary Shares

• See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Shenasaby Investments Pty Ltd as trustee for the Shenasaby Trust	85,823 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Class changed	Ordinary Shares
Number acquired	293,394
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of fees based on formula set out in Notice of General Meeting lodged on ASX 18/04/2019 as follows: 68,681 - $0.1456 69,013 - $0.1449 75,700 - $0.1321 80,000 - $0.125
No. of securities held after change
SRV Custodians Pty Ltd SRV Nominees Pty Ltd Shenasaby Investments Pty Ltd Shenasaby Investments Pty Ltd as trustee for the Shenasaby Trust	7,570,000 Ordinary Shares 649,177 Ordinary Shares 12,500 Ordinary Shares 379,217 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued in lieu of fees for the period Jan 2019-April 2019 as approved by shareholders at a general meeting on 20 May 2019

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: if consideration is non-cash, provide details and an estimated valuation	N/A
Interest after changes	N/A

Part 3 – Closed Period

Part 3 – Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lars Lidgren
Date of last notice	11/05/2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd) Algora AB (Professor Lidgren is a director of Algora AB Ltd)
Date of change	21/05/2019
No. of securities held prior to change JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd) Algora AB (Professor Lidgren is a director ofAlgora AB Ltd)	240,118 Ordinary Shares 768,091 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Ordinary Shares	Ordinary Shares
Number acquired	110,001
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of fees based on formula set out in Notice of general meeting lodged on ASX 18/04/2019 as follows: 25,735 - $0.1456 25,879 - $0.1449 28,387 - $0.1321 30,000 - $0.125
No. of securities held after change JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd) Algora AB (Professor Lidgren is a director ofAlgora AB Ltd)	350,119 Ordinary Shares 768,091 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued in lieu of fees for the period Jan 2019-April 2019 as approved by sharehodlers at a general meeting on 20 May 2019

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

art 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited

ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Qi Xiao Zhou
Date of last notice	11/05/2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	21/05/2019
No. of securities held prior to change Qi Xiao Zhou	5,996,241 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Class	Ordinary Shares
Number acquired	84,266
Number disposed	-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated	valuation	Issued in lieu of fees based on formula set out in Notice of general meeting lodged on ASX 18/04/2019 as follows: 25,879 - $0.1449 28,387 - $0.1321 30,000 - $0.125
No. of securities held after change Qi Xiao Zhou	6,080,507 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued in lieu of fees for the period Feb 2019 -April 2019 as approved by sharehodlers at a general meeting on 20 May 2019

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3